Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Up 8.1% in April: Crecon Report
June 14, 2016
- No Higher Mortality Risk Including CV Death Observed with Alogliptin against Placebo: Takeda
June 14, 2016
- Dave Fredrickson Tapped as Next Chief of AstraZeneca Japan
June 13, 2016
- Takeda Looks to Join Top 10 List in Global Oncology Space in 2025
June 10, 2016
- FY2015 Earnings Roundup - 5: 10 Firms Unveil Mid-Term Biz Plans, Many Play It Safe
June 10, 2016
- Mitsubishi Gas Chemical, Nippon Kayaku Form JV for Antibody, Biosimilar Production
June 10, 2016
- Takeda Gets Worldwide Rights to Theravance’s GI Drug Candidate
June 10, 2016
- Jacques Nathan to Lead Sanofi Japan from July 1
June 10, 2016
- AZ Japan Pres. Baertschi to Become CEO of Grünenthal in October
June 9, 2016
- Takeda, Ultragenyx Ink Strategic Partnership on Rare Genetic Diseases
June 9, 2016
- Shionogi to Transfer 3 Off-Patent Cancer Drugs to Nichi-Iko
June 9, 2016
- FY2015 Earnings Roundup - 4: Generic Biz Strategies Revolving around AG Launches
June 9, 2016
- Kaketsuken Announces Plan for Production Restart, Says Flu Vaccine Output Will Be Lower
June 9, 2016
- Kyowa Kirin, Medgenics Team Up on Severe Pediatric IBD Treatment
June 8, 2016
- FY2015 Earnings Roundup - 3: Japan Market Stagnates despite No Drug Price Revision, Off-Patent Brands Weigh
June 8, 2016
- Takeda, Roivant Form Joint Venture for Women’s Health, Prostate Cancer; Takeda Transfers 2 Investigational Products
June 8, 2016
- FY2015 Earnings Roundup - 2: New Drugs Gain Traction Overseas to Underpin Japan Makers’ Financial Results
June 7, 2016
- PDUFA Date for Naldemedine Set for March 23, 2017
June 7, 2016
- Takecab Most Promoted Drug for 4 Months on End: Anterio
June 7, 2016
- FY2015 Earnings Roundup - 1: Operating Profits of Japan Makers Climb on Global Brands, Royalties
June 6, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…